Imron T. Aly

Client Work

• Hospira, Inc. v. Fresenius Kabi USA, LLC (Successfully represented Fresenius  Kabi in a  groundbreaking appeal that not only benefited the client’s generic version of Precedex, but further developed the “inherent obviousness” case law for generic drugs. For this case, Schiff’s IP practice received the Hatch-Waxman Impact Case of the Year award in 2020 by LMG Life Sciences.)
• Fresenius Kabi USA, LLC v. FERA Pharmaceuticals, LLC (Successfully represented Fresenius Kabi in obtaining a rare preliminary injunction in federal district court. The injunction barred our client’s competitor from launching a generic version of its patented formulation of levothyroxine, an injectable thyroid hormone. The District Court for the District of New Jersey granted the injunction on the basis that our client was likely to win its patent lawsuit against its competitor.)
• Nexus Pharmaceuticals, Inc. v. Nevakar Injectables, Inc. (Leading Nexus’s efforts to address compounding companies who sell unapproved versions of Nexus’s FDA-approved ready-to-use ephedrine sulfate product.)
• Medicure International, Inc. v. Nexus Pharmaceuticals, Inc. (Favorable settlement of this Hatch-Waxman litigation concerning the drug tirofiban hydrochloride)
• Allergan Sales, LLC et al. v. Sandoz, Inc. et al (Represented Sandoz in brimonidine and timolol (brand name Combigan) ANDA litigation)
• Vanda v. Lupin (Represented Lupin in iloperidone ANDA litigation)
• Alcon v. Lupin (Represented Lupin in olopatadine ANDA litigation)
• Horizon v. Lupin (Represented Lupin in naproxen/esomeprazole ANDA litigation)
• BMS v. Lupin (Represented Lupin in apixaban ANDA litigation)
• Sanofi v. Accord (Represented Accord in cabazitaxel ANDA litigation)
• Forest Labs v. Hikma (Represented Hikma in trial for asenapine maleate ANDA litigation)
• Cumberland Pharmaceuticals v. InnoPharma (Represented InnoPharma in acetylcysteine IV ANDA litigation)
• Antares v. Medac (Represented Antares in medical device autoinjector patent litigation)
• Cephalon v. Fresenius Kabi (Represented FK in arsenic trioxide ANDA litigation)
• Onyx Pharma v. Fresenius Kabi (Represented FK in carfilzomib ANDA litigation)
• Pfizer v. Fresenius Kabi (Represented FK in tigecycline 505(b)(2) trial)
• Merck v. Fresenius Kabi (Represented FK in caspofungin 505(b)(2) trial)
• Helsinn v. Fresenius Kabi (Represented FK in palonosetron ANDA litigation)
• Celgene v. Fresenius Kabi (Represented FK in romidepsin ANDA litigation)
• Mylan v. Fresenius Kabi (Represented FK in remifentanil ANDA litigation)
• Shire Canada et al. v. Alkem Laboratories Ltd. (Represented Alkem in lanthanum carbonate ANDA litigation)
• King Pharma Inc. and Meridian Medical Technologies Inc v. Teva Pharmaceuticals (Represented Teva in epinephrine injector ANDA litigation)
• Aventis Pharma, S.A. and Sanofi-aventis Inc. v. Hospira Inc. (Represented Hospira including at trial in defending patent infringement claims for pharmaceutical involving docetaxel for cancer treatments)
• Boehringer et al. v. Barr Laboratories (Represented Barr Laboratories in defending patent infringement claims for pharmaceutical involving dipyradimole for stroke prevention)
• Sepracor Inc. v. Barr Laboratories Inc. (Represented Barr Laboratories in defending patent infringement claims for pharmaceutical involving levalbuterol for asthma treatments)
• Maytag Corporation v. Whirlpool Corp. (Represented Whirlpool in defending patent infringement claims concerning mechanical dispensing systems technology)
• Sears v. Bed Bath & Beyond (Represented Sears in patent case regarding electronic gift registry system)
• Johnson Controls Inc. v. Lear Corp. (Represented Lear in patent case regarding remote control garage door opener circuitry and encryption)
• Intellect Wireless v. Dell Inc. (Represented Dell in patent case involving cellular phone systems)
• Nanogen Inc. v. Motorola Inc. (Represented Motorola in patent litigation concerning biomedical DNA hybridization microchip technology)
• Computer Motion Inc. v. Intuitive Surgical Inc. (Represented Computer Motion in patent litigation concerning biomedical surgical robotics devices)
• Oxford Gene Technology Ltd. v. Mergen Ltd. (Represented OGT in asserting patent infringement claims concerning DNA hybridization microarray biomedical technology)
• Trading Technologies Intl. Inc. v. eSpeed Inc. (Represented eSpeed in defending patent infringement claims for a business-method patent concerning electronic futures trading)
• International Game Technology Inc. v. Aristocrat Leisure Ltd. (Represented IGT in a patent litigation focusing on business-method patents for electronic funds management and ticketing systems)

Previous Work

Imron’s career has focused on IP litigation, including at two large Chicago-based law firms. He also served as a law clerk for the Honorable Ann K. Covington, Missouri Supreme Court, from 1999-2000.

Professional Activities

• Guest Lecturer, Patent Litigation, University of Michigan (2011, 2013)
• Imron has represented indigent clients on a pro bono basis in trademark and copyright, contract dispute, landlord-tenant, prisoner rights, and elder abuse matters.

Boards, Memberships & Certifications

• Center for Biosimilars, Advisory Board Member
• Chicago Committee, Former Board Member
• Metropolitan Tenants Organization, Former Board Member

Publications, Presentations & Recognitions

Publications

• “Strategic Considerations When Managing and Protecting Disruptive Technologies,” Managing Intellectual Property Innovation and Litigation Summit 2019, San Francisco , Calif. (Jun. 11, 2019)
• “Judge Allows Alternative Biologics Challenge,” Schiff Hardin Insight (Mar. 24, 2015)
• “Myriad Faces Yet Another Patent Eligibility Battle In Return to the Federal Circuit,” Schiff Hardin Insight (Oct. 8, 2014)
• “New Developments in U.S. Hatch-Waxman Litigation,” IP Leadership Forum, New Delhi, India (2014)
• “Business Method Patents,” Software & Information Industry Association, Financial Information Services Division (2002) “Encouraging Professionalism: The Magic Wand of the Patent Infringement Opinion,” Georgetown Journal of Legal Ethics (1999)
• “Seller Beware: The Scope of the On Sale Bar after Pfaff v. Wells,” Texas Intellectual Property Law Journal (1999)

Recognitions

• IAM Patent 1000: The World’s Leading Patent Professionals, Patent Litigation, Illinois, IAM (2014-2022)
• Illinois Super Lawyers, Thomson Reuters (2015-2022)
• The Best Lawyers in America, Best Lawyers (2022-2024)
• Life Sciences Star – Hatch-Waxman Patent Litigation, LMG Life Sciences (2017-2022)
• The Legal 500 United States – Patents: Litigation (2021-2023)
• Chambers USA – Intellectual Property, Illinois (2018-2021)
• Illinois – Practitioner of the Year (Litigation) Shortlist, Managing IP America Awards (2021, 2023)
• Illinois Leading Lawyer, Law Bulletin’s Illinois Leading Lawyers Network (2017-2021)
• IP Star, Managing Intellectual Property (2015-2022)
• “Hatch-Waxman Litigator of the Year –Generic,” LMG Life Sciences (2020)
• Crain’s Chicago Business’ Notable Minorities in Accounting, Consulting & Law list (2020)
• Future Star, Euromoney’s Benchmark Litigation (2013, 2014, 2017-2018)
• Most Influential Minority Lawyer in Chicago, Crain’s Chicago Business (2017)
• Chambers USA – Up and Coming Leading Lawyer (2014)